TherapeuticsMD, Inc. 10-Q

Item 5. Other information Rule 10b5-1 Trading Plans During the three months ended March 31, 2025, none of the Company’s directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K). 28 Item 6. Exhibits Exhibit No. Description 31.1† Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) 31.2† Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) 32.1†† Section 1350 Certification of Chief Executive Officer 32.2†† Section 1350 Certification of Principal Financial Officer 101† Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q 104† Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set † Filed herewith. †† Furnished herewith. 29 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: May 13, 2025 TherapeuticsMD, Inc. /s/ Marlan D. Walker Marlan D. Walker Chief Executive Officer (Principal Executive Officer) /s/ Joseph Ziegler Joseph Ziegler Principal Financial and Accounting Officer 30